吡格列酮治疗非酒精性脂肪肝的疗效评价

Evaluation of the Efficacy of Pioglitazone in the Treatment of Non-alcoholic Fatty Liver

目的探讨非酒精性脂肪肝应用吡格列酮治疗的效果。方法简单随机抽取2018年5月—2020年5月该院收治的100例非酒精性脂肪肝患者为研究对象,依循不同入院时间将患者分为两组。对照组采用常规治疗方案进行对症治疗,观察组联合应用吡格列酮治疗。对比两组患者的谷丙转氨酶(ALT)、谷草转氨酶(AST)、胰岛素抵抗指数(HOMA-IR)、空腹血糖(FPG)、三酰甘油(TG)。结果观察组用药3、6个月后的ALT水平(60.22±21.32)、(34.27±10.28)U/L与AST水平(59.87±14.27)、(33.89±9.87)U/L均低于对照组(70.29±22.78)、(44.69±13.22)、(72.38±16.89)、(44.37±11.45)U/L,差异有统计学意义(t=2.282、4.400、4.001、4.902,P<0.05)。观察组用药3、6个月后的HOMA-IR(4.02±0.31)、(3.14±0.28),FPG水平(5.21±0.37)、(4.56±0.32)mmol/L,TG水平(1.80±0.25)、(1.54±0.20)mmol/L均低于对照组(4.89±0.35)、(3.99±0.31)、(5.78±0.40)mmol/L、(5.16±0.36)mmol/L、(2.10±0.30)mmol/L、(1.97±0.24)mmol/L,差异有统计学意义(t=13.158、14.388、7.397、8.808、5.432、9.733,P<0.001)。结论在常规治疗非酒精性脂肪肝的基础上联合应用吡格列酮治疗,可提升治疗效果,改善患者的肝功能、血糖、血脂水平以及胰岛素抵抗指数。

Objective To investigate the effect of pioglitazone treatment on non-alcoholic fatty liver.Methods From May 2018 to May 2020,100 patients with non-alcoholic fatty liver disease admitted to the hospital were Simple random selected as the research objects,and the patients were divided into two groups according to different admission times.The control group was treated with conventional treatment plan for symptomatic treatment,and the observation group was treated with pioglitazone in combination.The alanine aminotransferase(ALT),aspartate aminotransferase(AST),insulin resistance index(HOMA-IR),fasting blood glucose(FPG)and triacylglycerol(TG)were compared between the two groups of patients.Results The ALT levels(60.22±21.32)U/L,(34.27±10.28)U/L and AST levels(59.87±14.27)U/L and(33.89±9.87)U/L of the observation group after 3 and 6 months of medication were lower than those of the control group(70.29±22.78)U/L,(44.69±13.22)U/L,(72.38±16.89)U/L,(44.37±11.45)U/L,the difference was statistically significant(t=2.282,4.400,4.001,4.902,P<0.05).HOMA-IR(4.02±0.31),(3.14±0.28),FPG level(5.21±0.37)mmol/L,(4.56±0.32)mmol/L,TG level(1.80±0.25)mmol/L,(1.54±0.20)mmol/L in the observation group after 3 and 6 months of medication,were lower than the control group(4.89±0.35)mmol/L,(3.99±0.31)mmol/L,(5.78±0.40)mmol/L,(5.16±0.36)mmol/L,(2.10±0.30)mmol/L,(1.97±0.24)mmol/L,the difference was statistically significant(t=13.158,14.388,7.397,8.808,5.432,9.733,P<0.001).Conclusion The combined application of pioglitazone treatment on the basis of conventional treatment of non-alcoholic fatty liver can enhance the treatment effect and improve the patient's liver function,blood sugar,blood lipid level and insulin resistance index.